Brief: Hemab Therapeutics Reports Second Quarter 2026 Financial Results And Provides Corporate Update
11/08/2026 12:50
BRIEF-Hemab Therapeutics Reports Second Quarter 2026 Financial Results And Provides Corporate Update Aug 11 (Reuters) - Hemab Therapeutics Holdings Inc COAG.O:
HEMAB THERAPEUTICS REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
HEMAB THERAPEUTICS - Q2 NET LOSS $24.20 MILLION, OR $0.80 PER SHARE
Source text: ID:nGNX6LvmQ3
Further company coverage: COAG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hemab Therapeutics Holdings
See all newsUS RESEARCH ROUNDUP-BlackRock, Microsoft, TransDigm Group
U.S. RESEARCH ROUNDUP-Cardinal Health, Lumentum Holdings, Public Storage
Brief: Hemab Therapeutics Reports Second Quarter 2026 Financial Results And Provides Corporate Update
Biotech firm Odyssey raises $279 million in upsized US IPO (updated)
NASDAQ RESUMED AT 12:30 PM